Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients.

BACKGROUND: In Colombia and worldwide, breast cancer (BC) is the most frequently diagnosed neoplasia and the leading cause of death from cancer among women. Studies predominantly involve hereditary and familial cases, demonstrating a gap in the literature regarding the identification of germline mutations in unselected patients from Latin-America. Identification of pathogenic/likely pathogenic (P/LP) variants is important for shaping national genetic analysis policies, genetic counseling, and early detection strategies. The present study included 400 women with unselected breast cancer (BC), in whom we analyzed ten genes, using Whole Exome Sequencing (WES), know to confer risk for BC, with the aim of determining the genomic profile of previously unreported P/LP variants in the affected population. Additionally, Multiplex Ligation-dependent Probe Amplification (MLPA) was performed to identify Large Genomic Rearrangements (LGRs) in the BRCA1/2 genes. To ascertain the functional impact of a recurrent intronic variant (ATM c.5496 + 2_5496 + 5delTAAG), a minigene assay was conducted. RESULTS: We ascertained the frequency of P/LP germline variants in BRCA2 (2.5%), ATM (1.25%), BRCA1 (0.75%), PALB2 (0.50%), CHEK2 (0.50%), BARD1 (0.25%), and RAD51D (0.25%) genes in the population of study. P/LP variants account for 6% of the total population analyzed. No LGRs were detected in our study. We identified 1.75% of recurrent variants in BRCA2 and ATM genes. One of them corresponds to the ATM c.5496 + 2_5496 + 5delTAAG. Functional validation of this variant demonstrated a splicing alteration probably modifying the Pincer domain and subsequent protein structure. CONCLUSION: This study described for the first time the genomic profile of ten risk genes in Colombian women with unselected BC. Our findings underscore the significance of population-based research, advocating the consideration of molecular testing in all women with cancer.

Next-generation sequencing of host genetics risk factors associated with COVID-19 severity and long-COVID in Colombian population.

Coronavirus disease 2019 (COVID-19) was considered a major public health burden worldwide. Multiple studies have shown that susceptibility to severe infections and the development of long-term symptoms is significantly influenced by viral and host factors. These findings have highlighted the potential of host genetic markers to identify high-risk individuals and develop target interventions to reduce morbimortality. Despite its importance, genetic host factors remain largely understudied in Latin-American populations. Using a case-control design and a custom next-generation sequencing (NGS) panel encompassing 81 genetic variants and 74 genes previously associated with COVID-19 severity and long-COVID, we analyzed 56 individuals with asymptomatic or mild COVID-19 and 56 severe and critical cases. In agreement with previous studies, our results support the association between several clinical variables, including male sex, obesity and common symptoms like cough and dyspnea, and severe COVID-19. Remarkably, thirteen genetic variants showed an association with COVID-19 severity. Among these variants, rs11385942 (p < 0.01; OR = 10.88; 95% CI = 1.36-86.51) located in the LZTFL1 gene, and rs35775079 (p = 0.02; OR = 8.53; 95% CI = 1.05-69.45) located in CCR3 showed the strongest associations. Various respiratory and systemic symptoms, along with the rs8178521 variant (p < 0.01; OR = 2.51; 95% CI = 1.27-4.94) in the IL10RB gene, were significantly associated with the presence of long-COVID. The results of the predictive model comparison showed that the mixed model, which incorporates genetic and non-genetic variables, outperforms clinical and genetic models. To our knowledge, this is the first study in Colombia and Latin-America proposing a predictive model for COVID-19 severity and long-COVID based on genomic analysis. Our study highlights the usefulness of genomic approaches to studying host genetic risk factors in specific populations. The methodology used allowed us to validate several genetic variants previously associated with COVID-19 severity and long-COVID. Finally, the integrated model illustrates the importance of considering genetic factors in precision medicine of infectious diseases.

Functional Analysis of BRCA1 3'UTR Variants Predisposing to Breast Cancer.

Purpose: Breast Cancer (BC) is the main female cancer diagnosed worldwide, and it has been described that few genes, such as BRCA1, have a high penetrance for this type of cancer. In this manuscript, we were interested in evaluating the effect of 3'UTR variants on BRCA1 expression. Patients and Methods: To accomplish this objective, Whole Exome Sequencing (WES) data of 400 patients with unselected BC was used to filter variants located in the region of interest of BRCA1 gene, finding two of them (c.*36C>G and c.*369_373del). miRGate and miRanda in silico tools were used to predict microRNA (miRNA) interaction. Results: The two variants (c.*36C>G, c.*369_373del) were predicted to affect miRNA interaction. After cloning of BRCA1 3'UTR into pMIR-Report vector, the construct was transfected into two BC cell lines (MDA-MB-231 and MCF-7), and the variant c.*36C>G evidenced overexpression of reporter gene luciferase, showing that the transcript was not being degraded by the miRNA in MDA-MB-231 cells. Conclusion: The variant seems to protect against Triple Negative BC probably due to the expression level of miRNA in this particular cell line (MDA-MB-231). This is consistent with the clinical history of the patients who harbor BC Hormone Receptors positive (HR+).

Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations.

Background: Genetic interindividual variability is associated with adverse drug reactions (ADRs) and affects the response to common drugs used in anesthesia. Despite their importance, these variants remain largely underexplored in Latin-American countries. This study describes rare and common variants found in genes related to metabolism of analgesic and anaesthetic drug in the Colombian population. Methods: We conducted a study that included 625 Colombian healthy individuals. We generated a subset of 14 genes implicated in metabolic pathways of common medications used in anesthesia and assessed them by whole-exome sequencing (WES). Variants were filtered using two pipelines: A) novel or rare (minor allele frequency-MAF <1%) variants including missense, loss-of-function (LoF, e.g., frameshift, nonsense), and splice site variants with potential deleterious effect and B) clinically validated variants described in the PharmGKB (categories 1, 2 and 3) and/or ClinVar databases. For rare and novel missense variants, we applied an optimized prediction framework (OPF) to assess the functional impact of pharmacogenetic variants. Allelic, genotypic frequencies and Hardy-Weinberg equilibrium were calculated. We compare our allelic frequencies with these from populations described in the gnomAD database. Results: Our study identified 148 molecular variants potentially related to variability in the therapeutic response to 14 drugs commonly used in anesthesiology. 83.1% of them correspond to rare and novel missense variants classified as pathogenic according to the pharmacogenetic optimized prediction framework, 5.4% were loss-of-function (LoF), 2.7% led to potential splicing alterations and 8.8% were assigned as actionable or informative pharmacogenetic variants. Novel variants were confirmed by Sanger sequencing. Allelic frequency comparison showed that the Colombian population has a unique pharmacogenomic profile for anesthesia drugs with some allele frequencies different from other populations. Conclusion: Our results demonstrated high allelic heterogeneity among the analyzed sampled, enriched by rare (91.2%) variants in pharmacogenes related to common drugs used in anesthesia. The clinical implications of these results highlight the importance of implementation of next-generation sequencing data into pharmacogenomic approaches and personalized medicine.

Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.

In genes related to drug pharmacokinetics, molecular variations determine interindividual variability in the therapeutic efficacy and adverse drug reactions. The assessment of single-nucleotide variants (SNVs) is used with growing frequency in pharmacogenetic practice, and recently, high-throughput genomic analyses obtained through next-generation sequencing (NGS) have been recognized as powerful tools to identify common, rare and novel variants. These genetic profiles remain underexplored in Latin-American populations, including Colombia. In this study, we investigated the variability of 35 genes included in the ADME core panel (absorption, distribution, metabolism, and excretion) by whole-exome sequencing (WES) of 509 unrelated Colombian individuals with no previous reports of adverse drug reactions. Rare variants were filtered according to the minor allele frequencies (MAF) <1% and potential deleterious consequences. The functional impact of novel and rare missense variants was assessed using an optimized framework for pharmacogenetic variants. Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases. Ancestry from WES data was inferred using the R package EthSEQ v2.1.4. Allelic frequencies were compared to other populations reported in the public gnomAD database. Our analysis revealed that rare missense pharmacogenetic variants were 2.1 times more frequent than common variants with 121 variants predicted as potentially deleterious. Rare loss of function (LoF) variants were identified in 65.7% of evaluated genes. Regarding variants with clinical pharmacogenetic effect, our study revealed 89 sequence variations in 28 genes represented by missense (62%), synonymous (22.5%), splice site (11.2%), and indels (3.4%). In this group, ABCB1, ABCC2, CY2B6, CYP2D6, DPYD, NAT2, SLC22A1, and UGTB2B7, are the most polymorphic genes. NAT2, CYP2B6 and DPYD metabolizer phenotypes demonstrated the highest variability. Ancestry analysis indicated admixture in 73% of the population. Allelic frequencies exhibit significant differences with other Latin-American populations, highlighting the importance of pharmacogenomic studies in populations of different ethnicities. Altogether, our data revealed that rare variants are an important source of variability in pharmacogenes involved in the pharmacokinetics of drugs and likely account for the unexplained interindividual variability in drug response. These findings provide evidence of the utility of WES for pharmacogenomic testing and into clinical practice.

Performance Comparison of a Duplex Implementation of the CDC EUA 2019-nCoV Assay with the Seegene Allplex-SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Nasopharyngeal Swab Samples.

RT-PCR tests have become the gold standard for detecting the SARS-CoV-2 virus in the context of the COVID-19 pandemic. Because of the extreme number of cases in periodic waves of infection, there is a severe financial and logistical strain on diagnostic laboratories. For this reason, alternative implementations and validations of academic protocols that employ the lowest cost and the most widely available equipment and reagents found in different regions are essential. In this study, we report an alternative implementation of the EUA 2019-nCoV CDC assay which uses a previously characterized duplex PCR reaction for the N1 and RNAse P target regions and an additional uniplex reaction for the N2 target region. Taking advantage of the Abbott m2000 Sample Preparation System and NEB Luna Universal Probe One-Step RT-qPCR kit, some of the most widely available and inexpensive nucleic acid extraction and amplification platforms, this modified test shows state-of-the-art analytical and clinical sensitivities and specificities when compared with the Seegene Allplex-SARS-CoV-2 assay. This implementation has the potential to be verified and implemented by diagnostic laboratories around the world to guarantee low-cost RT-PCR tests that can take advantage of widely available equipment and reagents.

Association Between the LZTFL1 rs11385942 Polymorphism and COVID-19 Severity in Colombian Population.

Genetic and non-genetic factors are responsible for the high interindividual variability in the response to SARS-CoV-2. Although numerous genetic polymorphisms have been identified as risk factors for severe COVID-19, these remain understudied in Latin-American populations. This study evaluated the association of non-genetic factors and three polymorphisms: ACE rs4646994, ACE2 rs2285666, and LZTFL1 rs11385942, with COVID severity and long-term symptoms by using a case-control design. The control group was composed of asymptomatic/mild cases (n = 61) recruited from a private laboratory, while the case group was composed of severe/critical patients (n = 63) hospitalized in the Hospital Universitario Mayor-Méderi, both institutions located in Bogotá, Colombia. Clinical follow up and exhaustive revision of medical records allowed us to assess non-genetic factors. Genotypification of the polymorphism of interest was performed by amplicon size analysis and Sanger sequencing. In agreement with previous reports, we found a statistically significant association between age, male sex, and comorbidities, such as hypertension and type 2 diabetes mellitus (T2DM), and worst outcomes. We identified the polymorphism LZTFL1 rs11385942 as an important risk factor for hospitalization (p < 0.01; OR = 5.73; 95% CI = 1.2-26.5, under the allelic test). Furthermore, long-term symptoms were common among the studied population and associated with disease severity. No association between the polymorphisms examined and long-term symptoms was found. Comparison of allelic frequencies with other populations revealed significant differences for the three polymorphisms investigated. Finally, we used the statistically significant genetic and non-genetic variables to develop a predictive logistic regression model, which was implemented in a Shiny web application. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC = 0.86; 95% confidence interval 0.79-0.93). These results suggest that LZTFL1 rs11385942 may be a potential biomarker for COVID-19 severity in addition to conventional non-genetic risk factors. A better understanding of the impact of these genetic risk factors may be useful to prioritize high-risk individuals and decrease the morbimortality caused by SARS-CoV2 and future pandemics.

Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population.

BACKGROUND: Paraoxonase-1 (PON1), a glycoprotein associated with serum high-density lipoprotein (HDL), has a central role in metabolizing lipid peroxides, exhibiting antiatherogenic properties. The polymorphism p.Q192R has been previously associated with coronary artery disease (CAD) susceptibility and clopidogrel response. PURPOSE: We aimed at investigating the association of PON1 p.Q192R with CAD and clopidogrel response in Colombian population. PATIENTS AND METHODS: The study was conducted among 163 patients diagnosed with CAD and treated with clopidogrel. The allele frequencies for the PON1 192Q and 192R alleles were determined in cases and Latin-American controls obtained from the public database gnomAD (n = 17,711). Response to clopidogrel was determined by assessing the platelet function using the INNOVANCE PFA-200 System. We determined the association between PON1 p.Q192R polymorphism, increased susceptibility to CAD and high on-treatment platelet reactivity (HPR) by using odds ratio (OR) and 95% confidence interval (CI) on four genetic models. RESULTS: The allele frequencies for the PON1 192Q and 192R alleles were 0.60 and 0.40, respectively. The allele distribution was found to be statistically different from the control group and other ethnic groups. The allele 192R was positively associated with decreased susceptibility to CAD under a dominant model (OR, 0.58; 95% CI, 0.42-0.8; P < 0.01). We found no association between the polymorphism and HPR. CONCLUSION: We propose that PON1 p.Q192R is a potentially useful marker for CAD susceptibility in the Colombian population and lacks association with HPR under clopidogrel treatment.

Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population.

BACKGROUND: Copy Number variation (CNVs) in genes related to drug absorption, distribution, metabolism and excretion (ADME) are relevant in the interindividual variability of drug response. Studies of the CNVs in ADME genes in Latin America population are lacking. The objective of the study was to identify the genetic variability of CNVs in CYP-450 and GST genes in a subgroup of individuals of Colombian origin. METHODS: Genomic DNA was isolated from 123 healthy individuals from a Colombian population. Multiplex Ligation-Dependent Probe Amplification (MLPA) was performed for the identification of CNVs in 40 genomic regions of 11 CYP-450 and 3 GST genes. The genetic variability, allelic and genotypic frequencies were analyzed. RESULTS: We found that 13 out of 14 genes had CNVs: 5 (35.7%) exhibited deletions and duplications, while 8 (57.1%) presented either deletions or duplications.. 33.3% of individuals carried deletions and duplications while 49.6% had a unique type of CNV (deletion or duplication). The allelic frequencies of the CYP and GST genes were 0 to 47.6% (allele null), 0 to 17.5% (duplicated alleles) and 37 to 100% (normal alleles). CONCLUSIONS: Our results describe, for the first time, the genomic profile of CNVs in a subgroup of Colombian population in GST and CYP-450 genes. GST genes indicated greater genetic variability than CYP-450 genes. The data obtained contributes to the knowledge of genetic profiles in Latin American subgroups. Although the clinical relevance of CNVs has not been fully established, it is a valuable source of pharmacogenetic variability data with potential involvement in the response to medications.

Uveitis and Multiple Sclerosis: Potential Common Causal Mutations.

Uveitis, defined as inflammation of the uveal tract of the eye, is a leading cause of blindness and visual impairment throughout the world. The etiology of uveitis is complex, and autoimmunity plays a major role in its pathogenesis. Intermediate uveitis (IU), a subtype of ocular inflammation, has been associated with systemic autoimmune disorders, specifically with multiple sclerosis (MS). This article reports a rare three-generation family with several members affected by IU (four siblings) and comorbid MS (two siblings fulfilling MS diagnostic criteria and a third sibling presenting some neurological symptoms). Based on the clinical findings, we captured and sequenced whole exomes of seven pedigree members (affected and unaffected). Using a recessive model of transmission with full penetrance, we applied genetic linkage analysis to define minimal critical regions (MCRs) in suggestive or nominal regions of linkage. In these MCRs, we defined functional (some pathogenic), novel, and rare mutations that segregated as homozygous in affected and heterozygous in unaffected family members. The genes harboring these mutations, including DGKI, TNFRSF10A, GNGT1, CPAMD8, and BAFF, which are expressed in both eye and brain tissues and/or are related to autoimmune diseases, provide new avenues to evaluate the inherited causes of these devastating autoimmune conditions.

Caracterización fenotípica y molecular de Escherichia coli productoras de Beta-Lactamasas de espectro extendido en pacientes ambulatorios de Lima, Perú / Phenotypic and molecular characterization of extended spectrum beta-lactamase producing strains of Escherichia coli in ambulatory patients in Lima, Peru

Objetivos: Determinar las características fenotípicas y genotípicas de las β-lactamasas de espectro extendido (BLEE) en E. coli aislados de cultivos de orina de pacientes de la comunidad en un laboratorio privado de la ciudad de Lima, Perú. Material y métodos: Se evaluaron 53 aislamientos de E. coli por dos métodos fenotípicos: Jarlier y CLSI, el perfil de susceptibilidad se realizó mediante disco difusión y la caracterización genotípica mediante PCR para los genes blaCTX-M, blaTEM y blaSHV. Resultados: Los 53 aislamientos productores de BLEE representaron el 16,30% del total de aislados de E. coli, afectando principalmente a mujeres mayores de 65 años. El perfil de susceptibilidad evidenció alta resistencia a AMP,CEF,CRO(100%), LEV(87%), NOR(92%), CIP y NAL(94%), CXM y CTX(96%),SXT(70%), ATM(75%) y TOB (85%); asimismo elevada sensibilidad a NIT e IPM(100%), AMK(91%) y FOF(73,6%). El tipo de gen bla más frecuente fue blaCTX-M (55%), seguido por la coexistencia blaCTX-M+TEM (24%), blaTEM (13%) y blaSHV (6%). Conclusiones: La frecuencia de E. coli productores de BLEE fue de 16,3%; siendo el gen tipo blaCTX-M el más frecuente, información valiosa para orientar la terapia antimicrobiana empírica.

Objective: To determine the phenotypic and genotypic features of extended spectrum beta-lactamase (ESBL) producing strains of Escherichia coli isolated from urine samples of patients attending outpatient services in a private laboratory in Lima, Peru. Methods: 53 E. coli isolates were evaluated using two phenotypic methods: Jarlier and CLSI, the susceptibility profile was performed using the disk diffusion method and the genotypic features were analyzed using PCR for detecting blaCTX-M, blaTEM y blaSHV genes. Results: The 53 ESBL producing strains of E. coli accounted for 16,30% of all E. coli isolates affecting mostly women older than 65 years. High resistant profile to AMP, CEF, CRO (100%), LEV (87%), NOR (92%), CIP, NAL (94%), CXM, CTX (96%), SXT (70%), ATM (75%) and TOB (85%) was observed. High susceptibility to NIT, IPM (100%), AMK (91%) and FOF (73.6%) was observed. The most frequent bla gen was blaCTX-M (55%), followed by blaCTX-M+TEM (24%), blaTEM (13%) and blaSHV (6%). Conclusions: The rate of ESBL producing strains of E. coli was 16.3% and the blaCTX-M gen was the most common gene type. These results provide valuable information for starting empiric antibiotic therapy in this setting.

Correlación genotipo-fenotipo y análisis molecular en pacientes con síndrome Down / Correlation genotype-phenotype and molecular analysis in patients with Down syndrome / Correlação genótipo-fenótipo e análise molecular em pacientes com síndrome de Down

El síndrome Down (SD) es la trisomía más común en humanos, presentándose en 1 de cada 745 nacidos vivos y es la causa más frecuente de retardo mental. El origen más observado de la trisomía es una no disyunción meiótica (95%), la cual generalmente es de origen materno, mientras un 5% se debe a errores post-cigóticos mitóticos. Objetivo: identificar el origen parental del cromosoma 21 extra, el momento del error no disyuncional y establecer una correlación entre estos eventos y las manifestaciones fenotípicas de los pacientes afectados. Materiales y métodos: se estudiaron cincuenta familias con un hijo con SD mediante el uso de cinco short tandem repeats (STR) a lo largo de 21q, se construyeron los haplotipos de cada paciente y sus padres, determinando el origen parental y el momento en que surgió el error no disyuncional. Resultados: en 80% de las familias el error fue en meiosis I y 20% en la meiosis II; 98% de los cromosomas adicionales fue de origen materno y 2% paterno. Se encontró correlación genotipo-fenotipo en ocho características estudiadas: cuello corto y ancho, tercera fontanela, labio inferior prominente, paladar estrecho y corto, raíz del hélix cruzando la concha, alopecia, pliegue único palmar y otras anomalías como nevus y xeroderma y eventos de recombinación en 24,5% de las familias analizadas. Conclusiones: la edad materna y la variación en el número de recombinaciones está asociada con no disyunciones meióticas I y II; se encontró correlación entre el momento del error no disyuncional y algunas variables clínicas.

Down Syndrome (DS) is the most common trisomy in human beings. Its incidence is estimated in one of 745 live births. On a global scale, it is the most frequent cause of mental retardation. The origin of this trisomy is due to a meiotic non-disjunction in about 95% of cases and is usually maternal, especially in women above 35 years of age. The remaining 5% is due to errors in post-zygotic mitosis. Objective: identify the parental origin of the extra chromosome 21, when the error is not disyuncional and establish a correlation between these events and phenotypic manifestations of the patients affected. Materials and methods: we studied fifty families with a child with DS, using 5 STRs markers along 21q which allowed identification of the origin of chromosome 21 additional parents, the time when the error occurred and recombination presents. The statistical analysis was done using the package SPSS version 15.0 for Windows. Results: in 80% of households in the error was meiosis I and 20% in meiosis II, 98% of the additional chromosomes was home maternal and paternal 2% similar to those reported by other authors, correlation was found genotype-phenotype characteristics studied at 8, neck short and wide, third fontanel, prominent lower lip, palate narrow and short, crossing hélix root of the shell, alopecia, single palm crease and other anomalies as nevi and xeroderma and recombination events in 24,5% of the families tested. Conclusions: the maternal age and variation in the number of recombination is not associated with disjunctions meiotics I and II genotype phenotype correlation was found, but the sample size should be expanded in order to establish with certainty that the correlations.

O síndrome de Down (SD) é a trissomia mais comum em humanos, apresentando-se em 1 de cada 745 nascidos vivos e é a causa mais frequentes de retardo mental. A origem mais observada da trissomia é uma não-disjunção meiótica (95%), a qual geralmente é de origem materna, enquanto um 5% se deve a erros pós-zigoticos mitóticos. Objetivo: identificar a origem parental do cromossoma 21 extra, o momento do erro não-disjuncional e estabelecer uma correlação entre estes eventos e as manifestações fenotípicas dos pacientes afetados. Materiais e métodos: se estudaram cinquenta famíliascom um filho com SD mediante o uso de cinco short tandem repeats (STR) ao longe de 21q, se construíram os haplótipos de cada paciente e seus pais, determinando a origem parental e o momento em que surgiu o erro não-disjuncional. Resultados: em 80% das famílias o erro foi em meiose I e 20% na meiose II; 98% dos cromossomas adicionais foi de origem materno e 2% paterno. Encontrou-se correlação genótipo-fenótipo em oito características estudadas: pescoço curto e amplo, terceira fontanela, lábio inferior proeminente, paladar apertado e curto, raiz da hélix a través da concha, alopecia, prega palmar única e outras anomalias como nevus e xeroderma e eventos de recombinação em 24,5% das famílias analisadas. Conclusões:a idade materna e a variação no número de recombinações está associada com não-disjunções meióticas I e II; encontrou-se correlação entre o momento do erro não disjuncional e algumas variáveis clínicas.

Eficacia comparada del cotrimoxazol y la tetraciclina en el tratamiento del cólera / Comparative efficacy of cotrimoxazole and tetracycline in the treatment of cholera

El objetivo del presente estudio fue comparar la eficacia bactericida de la tetracilcina y el cotrimoxazol (combinación de sulfametoxazol y trimetoprina) en casos de cólera. El estudio se realizó en marzo de 1993 en la unidad de tratamiento del cólera (UTC) del hospital de Apoyo Departamental María Auxiliadora (HADMA) en Lima, Perú. Se trata de un estudio abierto y aleatorio en pacientes adultos con cólera confirmado por coprocultivo. Los pacientes se distribuyeron en dos grupos: los del grupo A recibieron 500 mg de tetracicliona cada 6 horas por vía oral durante 3 días; los del grupo B fueron tratados con cotrimoxazol a razón de 160 mg de trimetoprima y 800 mg de sulfametoxazol cada 12 horas por vía oral durante 3 días. En total se estudió a 107 pacientes, 50 en el grupo A y 57 en el B. Ambos grupos resultaron comparables en edad, sexo, duración de los síntomas antes del ingreso, momento en que se inició el tratamiento con antibióticos y evolución clínica. El coprocultivo de control después del tratamiento reveló Vibrio cholerae 01 en 2 por ciento de los pacientes del grupo A y en 12, 3 por ciento del los del grupo B, y V. cholerae NO-01 en 2 por ciento de los pacientes del grupo A y en 3,5 por ciento de los del grupo B. Se concluye que ambos esquemas terapéuticos son eficaces y que las cepas de V. cholerae observadas en la parte sur de la ciudad de Lima, Perú siguen sensibles a ambos antibióticos

Comparative effectiveness of co-trimoxazole and tetracycline in the treatment of cholera

The purpose of the study reported here was to compare the bactericidal effectiveness of tetracycline and co-trimoxazole (a combination of sulfamethoxazole and trimethoprim) in treating cholera. The study, an open-ended random trial using adult patients with cholera cases confirmed by stool culture, was carried out in March 1993 at the Cholera Treatment Unit (CTU) of the Hospital de Apoyo Departamental María Auxiliadora in Lima, Peru. A total of 107 subjects were divided into two groups (A and B). The 50 in Group A received 500 mg of tetracycline orally every 6 hours for 3 days; the 57 in Group B received co-trimoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole) orally every 12 hours for 3 days. The two groups were comparable in terms of age, sex, duration of symptoms prior to hospital admission, time at which antibiotic treatment was initiated, and clinical evolution. Control stool cultures of specimens obtained after treatment showed Vibrio cholerae 0-1 present in 2 percent of the Group A and 12.3 percent of the Group B patients, and also showed V. cholerae non-0-1 present in 2 percent of the group A patients and 3.5 percent of the Group B patients. Overall, it was concluded that both therapeutic treatment regimens were effective and that the strains of V. cholerae observed in the southern sector of the city of Lima were still susceptible to both antibiotics (AU)

Eficacia comparada del cotrimoxazol y la tetraciclina en el tratamiento del cólera / Comparative efficacy of cotrimoxazole and tetracycline in the treatment of cholera

El objetivo del presente estudio fue comparar la eficacia bactericida de la tetracilcina y el cotrimoxazol (combinación de sulfametoxazol y trimetoprina) en casos de cólera. El estudio se realizó en marzo de 1993 en la unidad de tratamiento del cólera (UTC) del hospital de Apoyo Departamental María Auxiliadora (HADMA) en Lima, Perú. Se trata de un estudio abierto y aleatorio en pacientes adultos con cólera confirmado por coprocultivo. Los pacientes se distribuyeron en dos grupos: los del grupo A recibieron 500 mg de tetracicliona cada 6 horas por vía oral durante 3 días; los del grupo B fueron tratados con cotrimoxazol a razón de 160 mg de trimetoprima y 800 mg de sulfametoxazol cada 12 horas por vía oral durante 3 días. En total se estudió a 107 pacientes, 50 en el grupo A y 57 en el B. Ambos grupos resultaron comparables en edad, sexo, duración de los síntomas antes del ingreso, momento en que se inició el tratamiento con antibióticos y evolución clínica. El coprocultivo de control después del tratamiento reveló Vibrio cholerae 01 en 2 por ciento de los pacientes del grupo A y en 12, 3 por ciento del los del grupo B, y V. cholerae NO-01 en 2 por ciento de los pacientes del grupo A y en 3,5 por ciento de los del grupo B. Se concluye que ambos esquemas terapéuticos son eficaces y que las cepas de V. cholerae observadas en la parte sur de la ciudad de Lima, Perú siguen sensibles a ambos antibióticos

Se publica en inglés en el Bull. PAHO Vol. 29(3), 1995

Comparative effectiveness of co-trimoxazole and tetracycline in the treatment of cholera

The purpose of the study reported here was to compare the bactericidal effectiveness of tetracycline and co-trimoxazole (a combination of sulfamethoxazole and trimethoprim) in treating cholera. The study, an open-ended random trial using adult patients with cholera cases confirmed by stool culture, was carried out in March 1993 at the Cholera Treatment Unit (CTU) of the Hospital de Apoyo Departamental María Auxiliadora in Lima, Peru. A total of 107 subjects were divided into two groups (A and B). The 50 in Group A received 500 mg of tetracycline orally every 6 hours for 3 days; the 57 in Group B received co-trimoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole) orally every 12 hours for 3 days. The two groups were comparable in terms of age, sex, duration of symptoms prior to hospital admission, time at which antibiotic treatment was initiated, and clinical evolution. Control stool cultures of specimens obtained after treatment showed Vibrio cholerae 0-1 present in 2 percent of the Group A and 12.3 percent of the Group B patients, and also showed V. cholerae non-0-1 present in 2 percent of the group A patients and 3.5 percent of the Group B patients. Overall, it was concluded that both therapeutic treatment regimens were effective and that the strains of V. cholerae observed in the southern sector of the city of Lima were still susceptible to both antibiotics (AU)

This article was also published in Spanish in the Bol. Oficina Sanit. Panam. Vol. 118(5):403-9, 1995

Paediatric campylobacter diarrhoea from household exposure to live chickens in Lima, Peru

Although Campylobacter jejuni is a frequent enteropathogen in cases of paediatric diarrhoea in developing countries, its route of transmission is not well understood. An age-matched, case-control study of children with C. jejuni diarrhoea was therefore carried out in Lima, Peru, from January 1983 to April 1986 to identify the risk factors and vehicles of transmission. As cases, 104 children less than 3 years of ages were selected and compared with controls of the same age with non-gastrointestinal illnesses. Household exposure to live chickens was an important risk factor (odds ratio, 11; after adjusting for socioeconomic and environmental variables). Subjects in index households had a higher frequency of infection than those in control households, and infected young children were more likely to be ill than older children for adults, suggesting that immunity may be acquired from natural infection. The risk factors identified suggest that direct contact with the faeces of C. jejuni-infected chickens in the household environment was largely responsible for transmission of the organism to susceptibles infants